Tojo González Rafael, Suarez Gonzalez Adolfo, Rúas Madiedo Patricia, Mancebo Mata Alejo, Pipa Muñiz María, Barreiro Alonso Eva, Roman Llorente Francisco Javier, Moro Villar María Carmen, Arce González Marta María, Villegas Diaz María Francisca, Mosquera Sierra Eugenia, Ruiz Ruiz Mónica
Aparato Digestivo, Hospital de Cabueñes Gijón..
Aparato Digestivo, Hospital Universitario Central de Asturias..
Nutr Hosp. 2015 Feb 7;31 Suppl 1:83-8. doi: 10.3305/nh.2015.31.sup1.8713.
Irritable bowel syndrome (IBS) is characterized by symptoms of abdominal pain and altered bowel habits. This common disorder is managed by varying clinical styles as no dominant therapeutic strategy has emerged. The pathophysiology of IBS remains unknown, but several lines of evidence link this disorder with the gut microbiota. Although controversy exists, gut microbiota is likely contributing to symptoms of IBS, at least in some patients, through an altered fermentation process, an impaired intestinal barrier function, a harmful modulation of enteric sensorimotor function, a promotion of low-grade inflammation without tissue damage, and a harmful modulation of the brain-gut axis. Probiotic therapy has a modest effect on IBS symptomatic relief, but the actual evidence is not strong enough to support a general recommendation of use. The best results are achieved, in children, with Lactobacillus rhamnusus GG, which moderately improves abdominal pain, while in adults the benefit appears to be greatest employing Bifidobacterium species.
肠易激综合征（IBS）的特征是腹痛和排便习惯改变。这种常见疾病的治疗方式多种多样，因为尚未出现占主导地位的治疗策略。IBS的病理生理学仍然未知，但有几条证据将这种疾病与肠道微生物群联系起来。尽管存在争议，但肠道微生物群可能至少在一些患者中通过改变发酵过程、损害肠道屏障功能、有害调节肠道感觉运动功能、促进无组织损伤的低度炎症以及有害调节脑-肠轴而导致IBS症状。益生菌疗法对缓解IBS症状有一定作用，但实际证据不够有力，不足以支持普遍推荐使用。在儿童中，使用鼠李糖乳杆菌GG可取得最佳效果，它能适度改善腹痛，而在成人中，使用双歧杆菌属似乎益处最大。
